Shuttle Pharmaceuticals Holdings, Inc. · NASDAQ:SHPH
Shuttle Pharmaceuticals — Investor Presentation (November 2022)
20 slides from Shuttle Pharmaceuticals's investor presentation, November 2022
Slide 1: Shuttle Pharmaceuticals Investor Presentation November 2022
Shuttle Pharmaceuticals, Inc. Nasdaq: SHPH Investor Presentation November 2022
Slide 2: Disclaimers
Disclaimers Forward Looking Statements All of the information contained within this business plan presentation (the “Presentation”) has been obtained from sources generally believed to be reliable by Shuttle Pharmaceuticals Holdings, Inc. (referred to herein as “Shuttle Pharmaceuticals,” “Shuttle” o
Slide 3: Experts in Radiation Oncology
Experts in Radiation Oncology Anatoly Dritschilo, M.D., is an experienced clinician and researcher who has held senior management and academic positions including Prior to co-founding Shuttle, Dr. Dritschilo was a co-founder of Oncomed, Inc., a company that became public as NeoPharm, Inc. (Nasda
Slide 4: Company Overview
Company Overview Shuttle Pharma (Nasdaq: SHPH) is a clinical-stage biopharma company developing next generation immuno-oncology and radio- oncology solutions for combined modality treatment of cancers, targeting a potential $4.5 Billion annual TAM, based on off-label use of radiation sensitizing d
Slide 5: The Fundamental Problem Facing Radiation Therapy
The Fundamental Problem Facing Radiation Therapy Cancers are surrounded by radiation sensitive normal tissues that limit the maximum treatment dose Strategies to overcome cancer resistance to radiation therapy: Sensitize Cancer Cells To Radiation Therapy Radiation sensitizers improve cancer cont
Slide 6: Lead Drug Candidates
Lead Drug Candidates Objective is to improve the outcomes of cancer treatment through RT while reducing its side effects by: Sensitizing growing cancer cells to render them more susceptible to the effects of RT; Activating the DNA damage response pathway to protect normal cells located near canc
Slide 7: Competitive Landscape
Competitive Landscape Cancers treated Side-effects Tot. Revenue (est.) “OFF-LABEL” Sensitizer Used 5- Flourouracil (Adrucil) Colon and rectal cancer Breast Cancer Enteritis Transient lymphocytopenia $19 million* with Radiation Therapy Patent expiry: 1977 Pancreatic cancer Nausea Capecita
Slide 8: Market Opportunity
Market Opportunity Immuno-therapies and radiation sensitizers are expected to improve outcomes in many cancers #2 ~ 1.8 M new cancer cases annually in the U.S. ~ 450,000 patients with local/regional cancers are candidates for RT with sensitizers ~ “Off-label” use of radiation sensitizing drugs predo
Slide 9: Clinical Pipeline
Clinical Pipeline Pipeline composed of two parts: Ropidoxuridine, our lead clinical drug candidate, which sensitizes rapidly growing cancer cells and, various selective HDAC (histone deacetylase) inhibitors – which sensitize cancer cells and stimulate the immune system. 9 Shuttle Pharmaceuticals Hol
Slide 10: Ropidoxuridine Platform: Overview
Ropidoxuridine Platform: Overview Ropidoxuridine (IPdR) is an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties. Halogenated pyrimidines are incorporated into DNA by rapidly growing cancer cells and the cells become more sensitive to the effects of RT.
Slide 11: Ropidoxuridine Platform: Clinical Studies
Ropidoxuridine Platform: Clinical Studies Ropidoxuridine (IPdR) is the prodrug of IUdR IUdR is a powerful radiation sensitizer showing Phase II efficacy in NIH sponsored clinical trials IUdR and RT for sarcoma patients resulted in improved survival IUdR and RT for glioblastoma and anaplastic
Slide 12: Ropidoxuridine Platform: Recent Activities
Ropidoxuridine Platform: Recent Activities Manufacturing Agreement In September 2022, the Company announced it entered into an agreement with TCG GreenChem, Inc. to manufacture Ropidoxuridine, the Company's lead clinical sensitizer drug candidate, for use in formulating the drug product for test
Slide 13: Ropidoxuridine Platform: Next Steps
Ropidoxuridine Platform: Next Steps Develop Ropidoxuridine (IPdR) for Orphan disease indications to take to market “We are preparing the Manufacture 24 kg of Ropidoxuridine and formulate for use in clinical trials. Investigational New Drug Conduct a Phase II clinical trial of Ropidoxuridine, T
Slide 14: HDAC Inhibitor Platform: Overview
HDAC Inhibitor Platform: Overview The company has discovered novel HDAC inhibitor molecules and testing in preclinical models has shown cancer radiation sensitizing properties, normal tissue protective properties and selective HDAC6 inhibitory properties. Our HDAC inhibitor platform will be eval
Slide 15: HDAC Inhibitor Platform: SP-2-225 Immuno-activator and HDAC6 Target
HDAC Inhibitor Platform: SP-2-225 Immuno-activator and HDAC6 Target Targeting HDAC6 for SM1 melanoma tumor growth inhibition S u rfa c e E x p re s s io n o f M H C I + S IIN F E K L 2 .5 UT 2 .0 RT 225 M F I R a t io 1 .5 225+RT 1 .0 0 .5 0 .0 5 T T T 22 R U R 5+ 22 SP-2-225 Induced Antigen Present
Slide 16: Intellectual Property Portfolio for Radiation Sensitizers
Intellectual Property Portfolio for Radiation Sensitizers Our intellectual property for Ropidoxuridine includes novel formulations that show improved drug bioavailability (in a preclinical animal model) and for sensitizing cancers to proton and to conventional radiation therapies. Our HDAC inhib
Slide 17: Summary: Clinical Development Strategy for Radiation Sensitizers
Summary: Clinical Development Strategy for Radiation Sensitizers Shuttle Pharma has a broad pipeline to improve clinical outcomes of patients treated with radiation therapy for cancer Priority #1: Advance Ropidoxuridine & RT to treat brain tumors (glioblastoma) Capitalize on Ropidoxuridine as
Slide 18: Financial Overview
Financial Overview Shuttle Pharmaceuticals Capital Market Profile Cap Table as of September 30, 2022 Common Stock 13,586,393 Exchange/Ticker NASDAQ: SHPH Fully Vested Restricted Stock Units (RSUs) 58,813 Closing Stock Price* $1.45 RSUs Subject to Vesting 369 52 Wk High/Low* $126.26 - $1.35 Warrants
Slide 19: Shuttle's Experienced Leadership Team
Shuttle’s Experienced Leadership Team Founder & CEO of Shuttle Served as President Served as CFO of Pharma since 2012. Chairman, & COO of Shuttle Shuttle Pharma since Board of Directors 2017 Pharma since 2012 2019 Member, Board of Directors, MBA George MHSA George Neopharm Inc. 1990 Wash
Slide 20: Thank You
THANK YOU Anatoly Dritschilo, MD CEO, Shuttle Pharmaceuticals Holdings, Inc. Tel: (240) 403-1212 Email: anatoly.dritschilo@ShuttlePharma.org 20
Shuttle Pharmaceuticals Holdings — Investor Presentation (November 2022) on 6ix